Clinical Trials

Multiple clinical trials evaluate L-aspartic acid across diverse therapeutic areas, including parenteral nutrition management, bipolar depression, acute lymphoblastic leukemia, and horizontal ridge augmentation. Spanning Phase 2, Phase 3, Phase 4, and unphased dental evaluations, these studies report recruitment statuses ranging from recruiting and completed to terminated. Sponsors include academic institutions such as Al-Azhar University and the Mayo Clinic collaborating with the National Institute of Mental Health, alongside industry entities including Baxter Healthcare Corporation and ERYtech Pharma.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06585852 RECRUITING
Implant Dentistry
Al-Azhar University
2023-08-01
NCT01923480 Terminated
Parenteral Nutrition (No Primary Condition Studied)
Baxter Healthcare Corporation
2013-07 Phase 4
NCT01042496 Completed
Bipolar Depression
Mayo Clinic|National Institute of Mental Health (NIMH)
2009-12 Phase 3
NCT01523782 Completed
Acute Lymphoblastic Leukemia
ERYtech Pharma
2009-04 Phase 2

(data from https://clinicaltrials.gov, updated on 2024-09-19)

Check the L-aspartic Acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

L-aspartic acid acts as a proteinogenic amino acid and excitatory neurotransmitter substrate that interacts with ionotropic glutamate receptors, driving intracellular metabolic pathways and excitatory signaling cascades. By modulating neuronal depolarization, cellular protein synthesis, and nitrogen homeostasis, L-aspartic acid supports metabolic regulation and central neurochemical dynamics relevant to clinical applications in parenteral nutrition, bipolar depression, and acute lymphoblastic leukemia.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.